Exploring Transformative Trends in Pharma Before CPHI Frankfurt 2025
As the pharmaceutical industry looks forward to the CPHI Frankfurt 2025, anticipation is building around pivotal transformations shaping the future of medicine. Solvias, a key player in chemistry, manufacturing, and control (CMC) analytics, is gearing up to engage with industry stakeholders and share insights on the trends that are set to redefine the pharma landscape.
One of the most anticipated discussions at CPHI will focus on the integration of artificial intelligence (AI), big data, and omics in analytics. Experts, like Daniel Galbraith, PhD, Chief Scientific Officer at Solvias, foresee a transformative impact as these technologies enable deeper insights into drug interactions at the cellular level. The convergence of these fields promises to usher in a new era where understanding drug effects is more comprehensive and nuanced.
Another focal point will be the expansion of high-resolution mass spectrometry within Good Manufacturing Practice (GMP) environments. Rafael Sande, Senior Director of Operations in Bioanalysis and Characterization, notes the increasing necessity for multi-attribute monitoring due to rising product complexity and regulatory demands. This trend signals a shift toward faster timelines and cost-control through advanced methodologies.
CPHI has consistently highlighted the accelerating pace of drug development, and this year, Solvias will advocate for the critical importance of CMC. With Andreas Hohenleutner, PhD, Senior Director of Operations in Drug Product CMC Characterization, emphasizing Quality by Design principles, the conversation will revolve around how companies can streamline approval processes amidst soaring expectations.
The spotlight at CPHI will likely shine on the burgeoning sector of small-molecule oral GLP-1 therapies, which are making waves for their potential to tackle obesity and diabetes effectively. As Achim Link, PhD, Field Development Services Manager, explains, Eli Lilly's Orforglipron is leading the charge, and its implications are set to reshape market dynamics by 2026. Solvias' expertise in impurity analysis positions them as vital partners in this evolving story.
Lastly, CPHI will explore groundbreaking innovations in drug delivery systems. With insights from Yannick Baschung, PhD, Associate Director of Drug Product Analysis, the dialogue will extend beyond traditional measures of drug stability and purity, highlighting the necessity of patient-centered design and in-silico modeling.
CPHI Frankfurt will take place from October 28-30, 2025, at the Messe Frankfurt, where professionals from across the global pharmaceutical network will gather. Solvias invites attendees to visit their booth at Stand 6.1D86 to learn more about these essential trends and explore how their services can support innovation and excellence in pharmaceutical development.
As Solvias continues to pave the way in CMC analytics, their focus on quality, reliability, and tailored solutions aims to foster partnerships that advance the pharmaceutical industry. With over 25 years of experience, their commitment to operational excellence and regulatory compliance ensures that they remain at the forefront of the life sciences sector. For further information about Solvias and their contributions to the global pharmaceutical landscape, visit solvias.com.
1. The Role of AI, Big Data, and Omics
One of the most anticipated discussions at CPHI will focus on the integration of artificial intelligence (AI), big data, and omics in analytics. Experts, like Daniel Galbraith, PhD, Chief Scientific Officer at Solvias, foresee a transformative impact as these technologies enable deeper insights into drug interactions at the cellular level. The convergence of these fields promises to usher in a new era where understanding drug effects is more comprehensive and nuanced.
2. Advancements in Mass Spectrometry
Another focal point will be the expansion of high-resolution mass spectrometry within Good Manufacturing Practice (GMP) environments. Rafael Sande, Senior Director of Operations in Bioanalysis and Characterization, notes the increasing necessity for multi-attribute monitoring due to rising product complexity and regulatory demands. This trend signals a shift toward faster timelines and cost-control through advanced methodologies.
3. The Critical Path of CMC Development
CPHI has consistently highlighted the accelerating pace of drug development, and this year, Solvias will advocate for the critical importance of CMC. With Andreas Hohenleutner, PhD, Senior Director of Operations in Drug Product CMC Characterization, emphasizing Quality by Design principles, the conversation will revolve around how companies can streamline approval processes amidst soaring expectations.
4. Emergence of Oral GLP-1 Small Molecules
The spotlight at CPHI will likely shine on the burgeoning sector of small-molecule oral GLP-1 therapies, which are making waves for their potential to tackle obesity and diabetes effectively. As Achim Link, PhD, Field Development Services Manager, explains, Eli Lilly's Orforglipron is leading the charge, and its implications are set to reshape market dynamics by 2026. Solvias' expertise in impurity analysis positions them as vital partners in this evolving story.
5. Innovations in Drug Delivery and Patient-Centric Design
Lastly, CPHI will explore groundbreaking innovations in drug delivery systems. With insights from Yannick Baschung, PhD, Associate Director of Drug Product Analysis, the dialogue will extend beyond traditional measures of drug stability and purity, highlighting the necessity of patient-centered design and in-silico modeling.
CPHI Frankfurt will take place from October 28-30, 2025, at the Messe Frankfurt, where professionals from across the global pharmaceutical network will gather. Solvias invites attendees to visit their booth at Stand 6.1D86 to learn more about these essential trends and explore how their services can support innovation and excellence in pharmaceutical development.
As Solvias continues to pave the way in CMC analytics, their focus on quality, reliability, and tailored solutions aims to foster partnerships that advance the pharmaceutical industry. With over 25 years of experience, their commitment to operational excellence and regulatory compliance ensures that they remain at the forefront of the life sciences sector. For further information about Solvias and their contributions to the global pharmaceutical landscape, visit solvias.com.
Topics Business Technology）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.